Moderna, Merck Report on Promising Melanoma Vaccine
Companies announced that the vaccine performed well in a small study of patients who had the cancer surgically removed
Companies announced that the vaccine performed well in a small study of patients who had the cancer surgically removed
Quality of life favored the pembrolizumab arm vs standard-of-care arm receiving ipilimumab, high-dose interferon α 2b
In phase 2 study, relatlimab and nivolumab combination immunotherapy resulted in pathologic complete response rate of 57 percent
Current evidence is insufficient for assessing balance of benefits and harms of screening for asymptomatic teens, adults
Robust antitumor activity and good tolerability observed in phase 2 study of nivolumab for first-line treatment of advanced cutaneous squamous cell carcinoma
Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition
In phase 2 study, about half of patients with resectable stage II to IV cutaneous squamous cell carcinoma had pathological complete response
Following an initial extensive review, the Agency identified less than 20 cases of SCC and less than 30 cases of various lymphomas in the capsule around the breast implant.
The proportion of excess cancer risk in men that was explained by risk factors was modest, ranging from 50 to 11 percent